Clinical Trial

EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors

Study acronym: EBNK-ST-001
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This Phase 1/2 study evaluates the safety, tolerability, and preliminary anti-tumor activity of EBNK-001 (allogeneic NK cells) given after lymphodepleting cyclophosphamide/fludarabine (CY/FLU) and supported with low-dose IL-15, administered either alone or in combination with pembrolizumab in adults with advanced/metastatic solid tumors. The study will determine a recommended Phase 2 dose (RP2D) and explore signals of clinical activity using RECIST-based response criteria.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-02-07.
Trial Details
NCT Number NCT07410676
Lead Sponsor Essen Biotech
Conditions Cancer, Sarcoma, Leukaemia, Breast Cancer (Locally Advanced or Metastatic), Lung Cancer (Diagnosis), Colorectal Cancer, Melanoma (Skin Cancer), Bladder Cancer +7 more
Enrollment 83 participants
Start Date 2026-02-01
Primary Completion 2028-12-21 (estimated)
Study Completion 2029-12-21 (estimated)
Updated on ClinicalTrials.gov 2026-02-18